Britain and America have finalized a significant trade agreement that will preserve no duties on UK drug products going into the American market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost expenditure on medicines through the NHS. This move guarantees that import taxes on these vital products will remain at nothing for a period of the next three years.
This deal is in response to recent warnings to hike duties on branded drug products, with figures mentioned up to double the cost.
"This arrangement between the Britain strengthens the global environment for innovative medicines and introduces much-needed equity to transatlantic pharmaceutical trade," a release noted.
Commercial Importance
Medicines are one of the Britain's largest exports to the United States, which is clearly the biggest buyer for leading UK drugmakers.
Export figures indicate that in the year to the end of September, the UK sold pharmaceutical products worth £11.1bn to the US. This figure accounted for nearly one-fifth of total UK exports in that span.
"This guarantee safeguards employment, boosts capital expenditure and facilitates the UK to become a worldwide center for medical research," a government official commented.
Specific UK Commitments
The pact entails several key changes from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to increase overall health service expenditure on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. Previously, rebates were more than twenty percent.
Broader Context
The deal follows a ongoing tension between the sector and the British authorities over medicine costs and regulatory access.
The disagreement were exacerbated by assertions that US customers were paying significantly more for the same drugs than people in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or cancelled, while substantial funding commitments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
